To resolve these issues, scientifically conducted, properly designed, controlled trials are needed to clarify the indications for treatment and to prevent the widespread use of growth hormone, if there is no proved benefit.
It was the purpose of this study to monitor closely the physical progress and the metabolic and psychological responses through childhood and puberty of a group of similarly aged, short children treated with growth hormone, and to compare them with an untreated group of short normal controls. Psychological responses will be reported separately.
A striking increase in height velocity after the first six months of treatment has already been reported and concern expressed about the implications of the marked lipolytic effect of growth hormone on body composition.9 This paper reports the continued progress of the trial over the first three years during the prepubertal phase.
Patients and methods Forty one short, normal children, of similar age and social class, whose heights were more than two standard deviations (SDs) below the mean according to the Tanner and Whitehouse standards,10 and who had an adequate stimulated growth hormone response, were entered into the trial. All the children had a stimulated growth hormone concentration greater than 7.5 ,ug/l (15 mU/l) to either clonidine or sleep, or both, ranging from 7-7 to 38.3 ,ug/l (15.4 to 76-5 mU/l). Only one child had a maximum stimulated growth hormone response between 7-5 and 10 ,ug/l (15 and 20 mU/l). Clinical examination and screening tests had already excluded any known pathology or recognisable causes of short stature. The subjects were randomly allocated either to the treated group (n=21) or to the untreated group (n= 20).
PATIENT CHARACTERISTICS
The mean (SD) age at the onset of the trial was 7-8 (0-5) years. There was a similar sex distribution with 1 1 boys and 10 girls in the treated group, and 12 boys and eight girls in the untreated group.
The mean birth weight for the two groups was similar, 2800 g in the treated and 2813 g in the untreated group. Two children in each group had birth weights below the third centile for gestational age. There was no difference between groups for admission rates to the special care baby unit.
On detailed comparison there was no difference between the treated and untreated groups at the onset of the trial with respect to age, sex, height, parental height, birth details, bone age delay, socioeconomic status, or evidence of psychosocial deprivation. TREATMENT 
REGIMEN
The treated group received recombinant human growth hormone, Genotropin, --I   ---centile   0  6  12  18  24  30  36 Time (months) Figure 1 Change in chronological age (years) Change in chronological age (years) Figure 2 Individual change in bone age against change in chronological age in treated and untreated (A) boys and (B) girls. Values from one treated boy missing as no baseline value.
reported,9 when the mean height velocity increased from 5-2 to 9 4 cm/year. After three years this group continued to grow significantly faster than the untreated group at a rate of 6-4 compared with 5-2 cm/year (p<0-003), equivalent to a height velocity SD score of 0-74 in the treated and -0-25 in the untreated groups. The velocity data are presented in table 1 as rolling 12 month velocities -that is, every six months velocities are calculated for the preceding 12 month period. When sitting height was expressed as a ratio with standing height, the mean ratio remained at 1-8 for the treated and untreated groups at each six monthly time interval. Thus no disproportionate growth was observed.
BONE MATURATION
The initial mean (SD) bone age for the treated group was 7-9 (1 1) years and in the untreated group was 6-6 (1-0) years when the mean chronological age was 8-0 years for the treated and 7-6 years for the untreated group. Bone age increased appropriately for chronological age in the two groups; the mean bone age increment was 3-1 years in the treated and 3-3 years in the untreated groups, whereas the chronological age increment was 3-1 years in the two groups. Figure 2 shows the individual change in bone age compared with the change in chronological age. When the height SD score was corrected for bone age, it still increased significantly in the treated group over the three year treatment period from -2-2 to -1-2, remaining unchanged in the Time (months) Figure 3 Mean (SEM) predicted adult height SD score in treated and untreated children.
untreated group at -1-7 (p<0-0001). The predicted adult height for the treated group significantly improved each year (p<0-0001), especially for the boys, with a minimum improvement noted in the untreated group. After three years the improvement in predicted adult height was 7-2 cm for all treated children (10-3 cm for boys, 4-0 cm for girls) compared with 1P4 cm for all untreated children (3-4 cm for boys, -0-6 cm for girls). The mean predicted adult height SD score in the treated group after three years was -1-1, which is equivalent to a final adult height prediction on the 15th centile ( fig 3) . The target height is the midparental height adjusted for sex and the target range is that within which 95% of eventual adult heights are expected to lie. 14 In our treated group of children, 93% of their predicted adult heights were below the target height at entry, whereas 53% were above it after three years of growth hormone treatment. The mean midparental height SD score was -1-4, equivalent to the ninth centile.
BODY COMPOSITION
Maximum fat loss in the treated group occurred in the first six months as previously reported.9 Although gradually regaining body fat, the treated children remained significantly leaner after three years, when body fat was 13.5% compared with 17.9% in the untreated children; p<0-015 (fig 4) . Similar patterns were observed in the two sexes, although the boys, treated and untreated, were slightly leaner than the girls. velocity SD score in the first 12 months were A slight increase was noted in the mean all compared with change in height SD score fasting blood glucose over three years in the over three years. treated group, but this was still within the When all the treated and untreated children normal range and not significantly different were considered, change in weight and IGF-1 from the untreated group. No change was seen correlated significantly with change in height in glycated haemoglobin concentrations in SD score. None of the other factors had any either group with a mean of 6-3% in the treated effect. When only the treated children were and 6-6% in the untreated groups at three years. considered, however, a change in IGF-1 and There was a significant increase in mean weight no longer correlated significantly with fasting insulin concentrations after the first growth response as assessed by a change in year of treatment in the treated group from height SD score.
20-8 to 50-2 pmol/l compared with a minimum increase in the untreated group from 24-4 to 31-6 pmol/l. A continuing increase in insulin was noted annually in the treated group, which reached a mean value of 66-7 pmol/l after three years of treatment, significantly higher than in the untreated group (p<0-0 1).
Four girls in each of the treated and untreated groups reached stage II puberty in the third year of the trial. When these girls were excluded from the insulin analysis, the mean fasting insulin for the children in stage 1 puberty was 63-9 pmol/l in the treated group, which was still significantly higher than 44-5 pmol/ in the untreated group (p<0-01).
Multiple regression analysis of a number of variables against insulin including IGF-1, height, weight, change in weight, velocity, velocity SD score, bone age, sex, and an indicator of those receiving treatment, showed a significant correlation of insulin with IGF-1 only. A clear linear relation was seen between these two correlates, with significant r values of 0-44 at entry and 0-66 at year 3 (p<0-01). 
Discussion
The ultimate aim of this longitudinal study is to resolve some of the issues surrounding the place of growth hormone in the treatment of short normal children and to rationalise its use. Short term improvement in height has been shown clearly in this study and in others,"8 but the long term outcome in terms of final adult height, safety, and wellbeing has yet to be
shown.
There are a number of features which are unique to this study. The children were originally drawn from the community and not the hospital clinic and were therefore free from referral bias. The age band is narrow and there are equal numbers of each sex. The continued monitoring of an untreated control group yields additional, comparative data. One of the difficulties in the interpretation of interventional studies affecting growth and development is the dynamic nature of growth data with increasing age. Thus it is vitally important to have a matched group of control subjects to aid in such interpretation. Many other similar studies lack the continuation of such a control group.
The dose ofgrowth hormone used in children in this study, 30 IU/m2/week, is higher than the standard dose used for idiopathic growth hormone deficiency, but is that suggested for the treatment of short normal children and certain clinical disorders such as Turner's syndrome and chronic renal failure.'5 16 It has been shown that a higher dose has a greater effect on growth response than lower dose regimens in the treatment of short normal children,3 6 although the optimum dose has not been defined. The 
week, as used in our study, has also been shown to be more effective than intermittent schedules. 5 17 A clear improvement in the rate of growth and final height potential was seen in boys and girls after the first three years of growth hormone treatment, as others have previously shown. The adult height prediction in our group was slightly better for boys, all of whom are prepubertal, with a significantly greater predicted final adult height on the 17th centile compared with the third centile predicted for the untreated boys. The final height prediction for the girls also improved to the 13th centile. Our data indicate that the higher dose of growth hormone given to short normal children does promote growth without affecting the rate of bone age maturation.
It has been suggested that growth hormone treatment shortens the amplitude and the duration of the pubertal growth spurt,18 19 which would result in no additional gain in final adult height but only a gain in earlier years. Other workers dispute this20 and in our present trial, four untreated girls just entered stage II puberty during the third year, as did four receiving treatment. There is, therefore, no indication in our study as yet that growth hormone is advancing the onset of puberty, nor is there any obvious relation between chronological age, bone age, and growth hormone treatment in the onset of puberty in these girls. During the next phase of the trial we shall be able to monitor the effect of this dose of growth hormone on the peak and duration of the pubertal growth spurt.
Concern was expressed in our first report of this study about changes in body composition. The loss in body fat noted in the first six months in the treated children was gradually regained over the following 18 Short normal children are sometimes referred to as children with idiopathic short stature. A precise and pure diagnosis in this group of children is difficult to ascertain and includes constitutional delay, familial short stature, and low birth weight. There is an overlap between constitutional delay and familial short stature, and it has not been found to be particularly helpful in determining response to treatment.24 Therefore we have not subclassified our children and, in addition, our numbers are too small. Low birth weight was not one of the exclusion criteria for entry into the trial. Although there are two low birthweight children in each group, we have not excluded them from the analysis at this stage as they appear to be responding as well as the others in terms of growth.
Hyperinsulinaemia in children treated with growth hormone has been noted by several other workers,4825 but only reported during the first year or two of treatmnent, levels returning to normal thereafter, or at the end of treatment. The precise cause of the persisting mild hyperinsulinaemia that we have observed is uncertain, but may be related to the high dose of growth hormone. A number of factors may be involved. Growth hormone is known to act directly on the , cell,26 thus increasing insulin production. It may also indirectly increase insulin by its effect on lipolysis, increasing hepatic glucose turnover and thus glucose stimulating insulin production. This has not been substantiated in short normal children, and although it theoretically may occur, the change in glucose turnover may be so small as to be difficult to measure.27 There is no evidence that prolonged hyperinsulinaemia is detrimental, but nor is there a good or appropriately comparable model.
In conclusion, we can confirm that growth hormone treatment has a positive effect on growth in short normal children in the short term, but, as has been stressed by others, the long term outcome in terms of final adult height and unwanted side effects is unknown. It is most important that longitudinal studies are completed and that final height data are collected. Secondly, we have noted persisting significant differences in body composition, with increased lean body mass, and also persisting hyperinsulinaemia in children treated with growth hormone. It is imperative that close monitoring, particularly of biochemical and body composition changes, is continually performed. Ultimately, we may be able to define specific treatment criteria, but further study is still required. 
